Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 19 entries
Sorted by: Best Match Show Resources per page
Long-Term Morbidity and Health After Early Menopause Due to Oophorectomy in Women at Increased Risk of Ovarian Cancer: Protocol for a Nationwide Cross-Sectional Study With Prospective Follow-Up (HARMOny Study).

JMIR research protocols

Terra L, Hooning MJ, Heemskerk-Gerritsen BAM, van Beurden M, Roeters van Lennep JE, van Doorn HC, de Hullu JA, Mom C, van Dorst EBL, Mourits MJE, Slangen BFM, Gaarenstroom KN, Zillikens MC, Leiner T, van der Kolk L, Collee M, Wevers M, Ausems MGEM, van Engelen K, Berger LP, van Asperen CJ, Gomez-Garcia EB, van de Beek I, Rookus MA, Hauptmann M, Bleiker EM, Schagen SB, Aaronson NK, Maas AHEM, van Leeuwen FE.
PMID: 33480862
JMIR Res Protoc. 2021 Jan 22;10(1):e24414. doi: 10.2196/24414.

BACKGROUND: BRCA1/2 mutation carriers are recommended to undergo risk-reducing salpingo-oophorectomy (RRSO) at 35 to 45 years of age. RRSO substantially decreases ovarian cancer risk, but at the cost of immediate menopause. Knowledge about the potential adverse effects of premenopausal...

Cite
Terra L, Hooning MJ, Heemskerk-Gerritsen BAM, et al. Long-Term Morbidity and Health After Early Menopause Due to Oophorectomy in Women at Increased Risk of Ovarian Cancer: Protocol for a Nationwide Cross-Sectional Study With Prospective Follow-Up (HARMOny Study). JMIR Res Protoc. 2021;10(1):e24414doi: 10.2196/24414.
Terra, L., Hooning, M. J., Heemskerk-Gerritsen, B. A. M., van Beurden, M., Roeters van Lennep, J. E., van Doorn, H. C., de Hullu, J. A., Mom, C., van Dorst, E. B. L., Mourits, M. J. E., Slangen, B. F. M., Gaarenstroom, K. N., Zillikens, M. C., Leiner, T., van der Kolk, L., Collee, M., Wevers, M., Ausems, M. G. E. M., van Engelen, K., Berger, L. P., van Asperen, C. J., Gomez-Garcia, E. B., van de Beek, I., Rookus, M. A., Hauptmann, M., Bleiker, E. M., Schagen, S. B., Aaronson, N. K., Maas, A. H. E. M., & van Leeuwen, F. E. (2021). Long-Term Morbidity and Health After Early Menopause Due to Oophorectomy in Women at Increased Risk of Ovarian Cancer: Protocol for a Nationwide Cross-Sectional Study With Prospective Follow-Up (HARMOny Study). JMIR research protocols, 10(1), e24414. https://doi.org/10.2196/24414
Terra, Lara, et al. "Long-Term Morbidity and Health After Early Menopause Due to Oophorectomy in Women at Increased Risk of Ovarian Cancer: Protocol for a Nationwide Cross-Sectional Study With Prospective Follow-Up (HARMOny Study)." JMIR research protocols vol. 10,1 (2021): e24414. doi: https://doi.org/10.2196/24414
Terra L, Hooning MJ, Heemskerk-Gerritsen BAM, van Beurden M, Roeters van Lennep JE, van Doorn HC, de Hullu JA, Mom C, van Dorst EBL, Mourits MJE, Slangen BFM, Gaarenstroom KN, Zillikens MC, Leiner T, van der Kolk L, Collee M, Wevers M, Ausems MGEM, van Engelen K, Berger LP, van Asperen CJ, Gomez-Garcia EB, van de Beek I, Rookus MA, Hauptmann M, Bleiker EM, Schagen SB, Aaronson NK, Maas AHEM, van Leeuwen FE. Long-Term Morbidity and Health After Early Menopause Due to Oophorectomy in Women at Increased Risk of Ovarian Cancer: Protocol for a Nationwide Cross-Sectional Study With Prospective Follow-Up (HARMOny Study). JMIR Res Protoc. 2021 Jan 22;10(1):e24414. doi: 10.2196/24414. PMID: 33480862; PMCID: PMC7864779.
Copy Download .nbib Format: NLM
Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study.

Breast (Edinburgh, Scotland)

Akdeniz D, van Barele M, Heemskerk-Gerritsen BAM, Steyerberg EW, Hauptmann M, van de Beek I, van Engelen K, Wevers MR, Gómez García EB, Ausems MGEM, Berger LPV, van Asperen CJ, Adank MA, Collée MJ, Stommel-Jenner DJ, Jager A, Schmidt MK, Hooning MJ.
PMID: 34929424
Breast. 2021 Dec 14;61:98-107. doi: 10.1016/j.breast.2021.12.007. Epub 2021 Dec 14.

AIM: BRCA1/2 mutation carriers with primary breast cancer (PBC) are at high risk of contralateral breast cancer (CBC). In a nationwide cohort, we investigated the effects of chemotherapeutic agents given for PBC on CBC risk separately in BRCA1 and...

Cite
Akdeniz D, van Barele M, Heemskerk-Gerritsen BAM, et al. Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study. Breast. 2021;61:98-107doi: 10.1016/j.breast.2021.12.007.
Akdeniz, D., van Barele, M., Heemskerk-Gerritsen, B. A. M., Steyerberg, E. W., Hauptmann, M., van de Beek, I., van Engelen, K., Wevers, M. R., Gómez García, E. B., Ausems, M. G. E. M., Berger, L. P. V., van Asperen, C. J., Adank, M. A., Collée, M. J., Stommel-Jenner, D. J., Jager, A., Schmidt, M. K., & Hooning, M. J. (2021). Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study. Breast (Edinburgh, Scotland), 6198-107. https://doi.org/10.1016/j.breast.2021.12.007
Akdeniz, Delal, et al. "Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study." Breast (Edinburgh, Scotland) vol. 61 (2021): 98-107. doi: https://doi.org/10.1016/j.breast.2021.12.007
Akdeniz D, van Barele M, Heemskerk-Gerritsen BAM, Steyerberg EW, Hauptmann M, van de Beek I, van Engelen K, Wevers MR, Gómez García EB, Ausems MGEM, Berger LPV, van Asperen CJ, Adank MA, Collée MJ, Stommel-Jenner DJ, Jager A, Schmidt MK, Hooning MJ. Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study. Breast. 2021 Dec 14;61:98-107. doi: 10.1016/j.breast.2021.12.007. Epub 2021 Dec 14. PMID: 34929424.
Copy Download .nbib Format: NLM
The effect of hormone therapy on breast density following risk-reducing salpingo-oophorectomy in women with an increased risk for breast and ovarian cancer.

Menopause (New York, N.Y.)

van Barele M, Buis CCM, Brood-van Zanten MMA, van Doorn HLC, Gaarenstroom KN, Heemskerk-Gerritsen BAM, Hooning MJ, de Hullu J, Mourits MJ, Burger CW.
PMID: 34374687
Menopause. 2021 Aug 09;28(11):1307-1312. doi: 10.1097/GME.0000000000001844.

OBJECTIVE: To compare the effect of tibolone to conjugated estrogens with medroxyprogesterone-acetate (CEE + MPA) on breast density, as a predictor for breast cancer risk, in women with a high risk of breast and ovarian cancer.METHODS: Women aged 30-50...

Cite
van Barele M, Buis CCM, Brood-van Zanten MMA, et al. The effect of hormone therapy on breast density following risk-reducing salpingo-oophorectomy in women with an increased risk for breast and ovarian cancer. Menopause. 2021;28(11):1307-1312doi: 10.1097/GME.0000000000001844.
van Barele, M., Buis, C. C. M., Brood-van Zanten, M. M. A., van Doorn, H. L. C., Gaarenstroom, K. N., Heemskerk-Gerritsen, B. A. M., Hooning, M. J., de Hullu, J., Mourits, M. J., & Burger, C. W. (2021). The effect of hormone therapy on breast density following risk-reducing salpingo-oophorectomy in women with an increased risk for breast and ovarian cancer. Menopause (New York, N.Y.), 28(11), 1307-1312. https://doi.org/10.1097/GME.0000000000001844
van Barele, Mark, et al. "The effect of hormone therapy on breast density following risk-reducing salpingo-oophorectomy in women with an increased risk for breast and ovarian cancer." Menopause (New York, N.Y.) vol. 28,11 (2021): 1307-1312. doi: https://doi.org/10.1097/GME.0000000000001844
van Barele M, Buis CCM, Brood-van Zanten MMA, van Doorn HLC, Gaarenstroom KN, Heemskerk-Gerritsen BAM, Hooning MJ, de Hullu J, Mourits MJ, Burger CW. The effect of hormone therapy on breast density following risk-reducing salpingo-oophorectomy in women with an increased risk for breast and ovarian cancer. Menopause. 2021 Aug 09;28(11):1307-1312. doi: 10.1097/GME.0000000000001844. PMID: 34374687.
Copy Download .nbib Format: NLM
Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study.

Breast (Edinburgh, Scotland)

Akdeniz D, van Barele M, Heemskerk-Gerritsen BAM, Steyerberg EW, Hauptmann M, van de Beek I, van Engelen K, Wevers MR, Gómez García EB, Ausems MGEM, Berger LPV, van Asperen CJ, Adank MA, Collée MJ, Stommel-Jenner DJ, Jager A, Schmidt MK, Hooning MJ.
PMID: 34929424
Breast. 2021 Dec 14;61:98-107. doi: 10.1016/j.breast.2021.12.007. Epub 2021 Dec 14.

AIM: BRCA1/2 mutation carriers with primary breast cancer (PBC) are at high risk of contralateral breast cancer (CBC). In a nationwide cohort, we investigated the effects of chemotherapeutic agents given for PBC on CBC risk separately in BRCA1 and...

Cite
Akdeniz D, van Barele M, Heemskerk-Gerritsen BAM, et al. Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study. Breast. 2021;61:98-107doi: 10.1016/j.breast.2021.12.007.
Akdeniz, D., van Barele, M., Heemskerk-Gerritsen, B. A. M., Steyerberg, E. W., Hauptmann, M., van de Beek, I., van Engelen, K., Wevers, M. R., Gómez García, E. B., Ausems, M. G. E. M., Berger, L. P. V., van Asperen, C. J., Adank, M. A., Collée, M. J., Stommel-Jenner, D. J., Jager, A., Schmidt, M. K., & Hooning, M. J. (2021). Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study. Breast (Edinburgh, Scotland), 6198-107. https://doi.org/10.1016/j.breast.2021.12.007
Akdeniz, Delal, et al. "Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study." Breast (Edinburgh, Scotland) vol. 61 (2021): 98-107. doi: https://doi.org/10.1016/j.breast.2021.12.007
Akdeniz D, van Barele M, Heemskerk-Gerritsen BAM, Steyerberg EW, Hauptmann M, van de Beek I, van Engelen K, Wevers MR, Gómez García EB, Ausems MGEM, Berger LPV, van Asperen CJ, Adank MA, Collée MJ, Stommel-Jenner DJ, Jager A, Schmidt MK, Hooning MJ. Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study. Breast. 2021 Dec 14;61:98-107. doi: 10.1016/j.breast.2021.12.007. Epub 2021 Dec 14. PMID: 34929424; PMCID: PMC8693290.
Copy Download .nbib Format: NLM
Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study.

Breast (Edinburgh, Scotland)

Akdeniz D, van Barele M, Heemskerk-Gerritsen BAM, Steyerberg EW, Hauptmann M, van de Beek I, van Engelen K, Wevers MR, Gómez García EB, Ausems MGEM, Berger LPV, van Asperen CJ, Adank MA, Collée MJ, Stommel-Jenner DJ, Jager A, Schmidt MK, Hooning MJ.
PMID: 34929424
Breast. 2021 Dec 14;61:98-107. doi: 10.1016/j.breast.2021.12.007. Epub 2021 Dec 14.

AIM: BRCA1/2 mutation carriers with primary breast cancer (PBC) are at high risk of contralateral breast cancer (CBC). In a nationwide cohort, we investigated the effects of chemotherapeutic agents given for PBC on CBC risk separately in BRCA1 and...

Cite
Akdeniz D, van Barele M, Heemskerk-Gerritsen BAM, et al. Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study. Breast. 2021;61:98-107doi: 10.1016/j.breast.2021.12.007.
Akdeniz, D., van Barele, M., Heemskerk-Gerritsen, B. A. M., Steyerberg, E. W., Hauptmann, M., van de Beek, I., van Engelen, K., Wevers, M. R., Gómez García, E. B., Ausems, M. G. E. M., Berger, L. P. V., van Asperen, C. J., Adank, M. A., Collée, M. J., Stommel-Jenner, D. J., Jager, A., Schmidt, M. K., & Hooning, M. J. (2021). Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study. Breast (Edinburgh, Scotland), 6198-107. https://doi.org/10.1016/j.breast.2021.12.007
Akdeniz, Delal, et al. "Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study." Breast (Edinburgh, Scotland) vol. 61 (2021): 98-107. doi: https://doi.org/10.1016/j.breast.2021.12.007
Akdeniz D, van Barele M, Heemskerk-Gerritsen BAM, Steyerberg EW, Hauptmann M, van de Beek I, van Engelen K, Wevers MR, Gómez García EB, Ausems MGEM, Berger LPV, van Asperen CJ, Adank MA, Collée MJ, Stommel-Jenner DJ, Jager A, Schmidt MK, Hooning MJ. Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study. Breast. 2021 Dec 14;61:98-107. doi: 10.1016/j.breast.2021.12.007. Epub 2021 Dec 14. PMID: 34929424; PMCID: PMC8693290.
Copy Download .nbib Format: NLM
Correction to: Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers.

Breast cancer research : BCR

Mavaddat N, Antoniou AC, Mooij TM, Hooning MJ, Heemskerk-Gerritsen BA, Noguès C, Gauthier-Villars M, Caron O, Gesta P, Pujol P, Lortholary A, Barrowdale D, Frost D, Evans DG, Izatt L, Adlard J, Eeles R, Brewer C, Tischkowitz M, Henderson A, Cook J, Eccles D, van Engelen K, Mourits MJE, Ausems MGEM, Koppert LB, Hopper JL, John EM, Chung WK, Andrulis IL, Daly MB, Buys SS, Benitez J, Caldes T, Jakubowska A, Simard J, Singer CF, Tan Y, Olah E, Navratilova M, Foretova L, Gerdes AM, Roos-Blom MJ, Van Leeuwen FE, Arver B, Olsson H, Schmutzler RK, Engel C, Kast K, Phillips KA, Terry MB, Milne RL, Goldgar DE, Rookus MA, Andrieu N, Easton DF.
PMID: 32102695
Breast Cancer Res. 2020 Feb 26;22(1):25. doi: 10.1186/s13058-020-01259-w.

After publication of the original article [1], we were notified that columns in Table 2 were erroneously displayed.

Cite
Mavaddat N, Antoniou AC, Mooij TM, et al. Correction to: Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers. Breast Cancer Res. 2020;22(1):25doi: 10.1186/s13058-020-01259-w.
Mavaddat, N., Antoniou, A. C., Mooij, T. M., Hooning, M. J., Heemskerk-Gerritsen, B. A., Noguès, C., Gauthier-Villars, M., Caron, O., Gesta, P., Pujol, P., Lortholary, A., Barrowdale, D., Frost, D., Evans, D. G., Izatt, L., Adlard, J., Eeles, R., Brewer, C., Tischkowitz, M., Henderson, A., Cook, J., Eccles, D., van Engelen, K., Mourits, M. J. E., Ausems, M. G. E. M., Koppert, L. B., Hopper, J. L., John, E. M., Chung, W. K., Andrulis, I. L., Daly, M. B., Buys, S. S., Benitez, J., Caldes, T., Jakubowska, A., Simard, J., Singer, C. F., Tan, Y., Olah, E., Navratilova, M., Foretova, L., Gerdes, A. M., Roos-Blom, M. J., Van Leeuwen, F. E., Arver, B., Olsson, H., Schmutzler, R. K., Engel, C., Kast, K., Phillips, K. A., Terry, M. B., Milne, R. L., Goldgar, D. E., Rookus, M. A., Andrieu, N., Easton, D. F. (2020). Correction to: Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers. Breast cancer research : BCR, 22(1), 25. https://doi.org/10.1186/s13058-020-01259-w
Mavaddat, Nasim, et al. "Correction to: Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers." Breast cancer research : BCR vol. 22,1 (2020): 25. doi: https://doi.org/10.1186/s13058-020-01259-w
Mavaddat N, Antoniou AC, Mooij TM, Hooning MJ, Heemskerk-Gerritsen BA, Noguès C, Gauthier-Villars M, Caron O, Gesta P, Pujol P, Lortholary A, Barrowdale D, Frost D, Evans DG, Izatt L, Adlard J, Eeles R, Brewer C, Tischkowitz M, Henderson A, Cook J, Eccles D, van Engelen K, Mourits MJE, Ausems MGEM, Koppert LB, Hopper JL, John EM, Chung WK, Andrulis IL, Daly MB, Buys SS, Benitez J, Caldes T, Jakubowska A, Simard J, Singer CF, Tan Y, Olah E, Navratilova M, Foretova L, Gerdes AM, Roos-Blom MJ, Van Leeuwen FE, Arver B, Olsson H, Schmutzler RK, Engel C, Kast K, Phillips KA, Terry MB, Milne RL, Goldgar DE, Rookus MA, Andrieu N, Easton DF. Correction to: Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers. Breast Cancer Res. 2020 Feb 26;22(1):25. doi: 10.1186/s13058-020-01259-w. PMID: 32102695; PMCID: PMC7045606.
Copy Download .nbib Format: NLM
Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study.

Breast (Edinburgh, Scotland)

Akdeniz D, van Barele M, Heemskerk-Gerritsen BAM, Steyerberg EW, Hauptmann M, van de Beek I, van Engelen K, Wevers MR, Gómez García EB, Ausems MGEM, Berger LPV, van Asperen CJ, Adank MA, Collée MJ, Stommel-Jenner DJ, Jager A, Schmidt MK, Hooning MJ.
PMID: 34929424
Breast. 2021 Dec 14;61:98-107. doi: 10.1016/j.breast.2021.12.007. Epub 2021 Dec 14.

AIM: BRCA1/2 mutation carriers with primary breast cancer (PBC) are at high risk of contralateral breast cancer (CBC). In a nationwide cohort, we investigated the effects of chemotherapeutic agents given for PBC on CBC risk separately in BRCA1 and...

Cite
Akdeniz D, van Barele M, Heemskerk-Gerritsen BAM, et al. Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study. Breast. 2021;61:98-107doi: 10.1016/j.breast.2021.12.007.
Akdeniz, D., van Barele, M., Heemskerk-Gerritsen, B. A. M., Steyerberg, E. W., Hauptmann, M., van de Beek, I., van Engelen, K., Wevers, M. R., Gómez García, E. B., Ausems, M. G. E. M., Berger, L. P. V., van Asperen, C. J., Adank, M. A., Collée, M. J., Stommel-Jenner, D. J., Jager, A., Schmidt, M. K., & Hooning, M. J. (2021). Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study. Breast (Edinburgh, Scotland), 6198-107. https://doi.org/10.1016/j.breast.2021.12.007
Akdeniz, Delal, et al. "Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study." Breast (Edinburgh, Scotland) vol. 61 (2021): 98-107. doi: https://doi.org/10.1016/j.breast.2021.12.007
Akdeniz D, van Barele M, Heemskerk-Gerritsen BAM, Steyerberg EW, Hauptmann M, van de Beek I, van Engelen K, Wevers MR, Gómez García EB, Ausems MGEM, Berger LPV, van Asperen CJ, Adank MA, Collée MJ, Stommel-Jenner DJ, Jager A, Schmidt MK, Hooning MJ. Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study. Breast. 2021 Dec 14;61:98-107. doi: 10.1016/j.breast.2021.12.007. Epub 2021 Dec 14. PMID: 34929424.
Copy Download .nbib Format: NLM
Estrogens and Progestogens in Triple Negative Breast Cancer: Do They Harm?.

Cancers

van Barele M, Heemskerk-Gerritsen BAM, Louwers YV, Vastbinder MB, Martens JWM, Hooning MJ, Jager A.
PMID: 34063736
Cancers (Basel). 2021 May 21;13(11). doi: 10.3390/cancers13112506.

Triple-negative breast cancers (TNBC) occur more frequently in younger women and do not express estrogen receptor (ER) nor progesterone receptor (PR), and are therefore often considered hormone-insensitive. Treatment of premenopausal TNBC patients almost always includes chemotherapy, which may lead...

Cite
van Barele M, Heemskerk-Gerritsen BAM, Louwers YV, et al. Estrogens and Progestogens in Triple Negative Breast Cancer: Do They Harm?. Cancers (Basel). 2021;13(11)doi: 10.3390/cancers13112506.
van Barele, M., Heemskerk-Gerritsen, B. A. M., Louwers, Y. V., Vastbinder, M. B., Martens, J. W. M., Hooning, M. J., & Jager, A. (2021). Estrogens and Progestogens in Triple Negative Breast Cancer: Do They Harm?. Cancers, 13(11), . https://doi.org/10.3390/cancers13112506
van Barele, Mark, et al. "Estrogens and Progestogens in Triple Negative Breast Cancer: Do They Harm?." Cancers vol. 13,11 (2021). doi: https://doi.org/10.3390/cancers13112506
van Barele M, Heemskerk-Gerritsen BAM, Louwers YV, Vastbinder MB, Martens JWM, Hooning MJ, Jager A. Estrogens and Progestogens in Triple Negative Breast Cancer: Do They Harm?. Cancers (Basel). 2021 May 21;13(11). doi: 10.3390/cancers13112506. PMID: 34063736; PMCID: PMC8196589.
Copy Download .nbib Format: NLM
Corrigendum to "The impact of menstruation persistence or recovery after chemotherapy on survival in young patients with hormone receptor negative breast cancer" [Breast 52 (2020) 102-109].

Breast (Edinburgh, Scotland)

van Barele M, Heemskerk-Gerritsen BAM, van Doorn HC, Schmidt MK, Hooning MJ, Jager A.
PMID: 32950229
Breast. 2020 Oct;53:221-222. doi: 10.1016/j.breast.2020.08.016.

No abstract available.

Cite
van Barele M, Heemskerk-Gerritsen BAM, van Doorn HC, et al. Corrigendum to "The impact of menstruation persistence or recovery after chemotherapy on survival in young patients with hormone receptor negative breast cancer" [Breast 52 (2020) 102-109]. Breast. 2020;53:221-222doi: 10.1016/j.breast.2020.08.016.
van Barele, M., Heemskerk-Gerritsen, B. A. M., van Doorn, H. C., Schmidt, M. K., Hooning, M. J., & Jager, A. (2020). Corrigendum to "The impact of menstruation persistence or recovery after chemotherapy on survival in young patients with hormone receptor negative breast cancer" [Breast 52 (2020) 102-109]. Breast (Edinburgh, Scotland), 53221-222. https://doi.org/10.1016/j.breast.2020.08.016
van Barele, Mark, et al. "Corrigendum to "The impact of menstruation persistence or recovery after chemotherapy on survival in young patients with hormone receptor negative breast cancer" [Breast 52 (2020) 102-109]." Breast (Edinburgh, Scotland) vol. 53 (2020): 221-222. doi: https://doi.org/10.1016/j.breast.2020.08.016
van Barele M, Heemskerk-Gerritsen BAM, van Doorn HC, Schmidt MK, Hooning MJ, Jager A. Corrigendum to "The impact of menstruation persistence or recovery after chemotherapy on survival in young patients with hormone receptor negative breast cancer" [Breast 52 (2020) 102-109]. Breast. 2020 Oct;53:221-222. doi: 10.1016/j.breast.2020.08.016. PMID: 32950229; PMCID: PMC7503791.
Copy Download .nbib Format: NLM
Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study.

Breast (Edinburgh, Scotland)

Akdeniz D, van Barele M, Heemskerk-Gerritsen BAM, Steyerberg EW, Hauptmann M, van de Beek I, van Engelen K, Wevers MR, Gómez García EB, Ausems MGEM, Berger LPV, van Asperen CJ, Adank MA, Collée MJ, Stommel-Jenner DJ, Jager A, Schmidt MK, Hooning MJ.
PMID: 34929424
Breast. 2021 Dec 14;61:98-107. doi: 10.1016/j.breast.2021.12.007. Epub 2021 Dec 14.

AIM: BRCA1/2 mutation carriers with primary breast cancer (PBC) are at high risk of contralateral breast cancer (CBC). In a nationwide cohort, we investigated the effects of chemotherapeutic agents given for PBC on CBC risk separately in BRCA1 and...

Cite
Akdeniz D, van Barele M, Heemskerk-Gerritsen BAM, et al. Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study. Breast. 2021;61:98-107doi: 10.1016/j.breast.2021.12.007.
Akdeniz, D., van Barele, M., Heemskerk-Gerritsen, B. A. M., Steyerberg, E. W., Hauptmann, M., van de Beek, I., van Engelen, K., Wevers, M. R., Gómez García, E. B., Ausems, M. G. E. M., Berger, L. P. V., van Asperen, C. J., Adank, M. A., Collée, M. J., Stommel-Jenner, D. J., Jager, A., Schmidt, M. K., & Hooning, M. J. (2021). Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study. Breast (Edinburgh, Scotland), 6198-107. https://doi.org/10.1016/j.breast.2021.12.007
Akdeniz, Delal, et al. "Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study." Breast (Edinburgh, Scotland) vol. 61 (2021): 98-107. doi: https://doi.org/10.1016/j.breast.2021.12.007
Akdeniz D, van Barele M, Heemskerk-Gerritsen BAM, Steyerberg EW, Hauptmann M, van de Beek I, van Engelen K, Wevers MR, Gómez García EB, Ausems MGEM, Berger LPV, van Asperen CJ, Adank MA, Collée MJ, Stommel-Jenner DJ, Jager A, Schmidt MK, Hooning MJ. Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study. Breast. 2021 Dec 14;61:98-107. doi: 10.1016/j.breast.2021.12.007. Epub 2021 Dec 14. PMID: 34929424; PMCID: PMC8693290.
Copy Download .nbib Format: NLM
Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study.

Breast (Edinburgh, Scotland)

Akdeniz D, van Barele M, Heemskerk-Gerritsen BAM, Steyerberg EW, Hauptmann M, van de Beek I, van Engelen K, Wevers MR, Gómez García EB, Ausems MGEM, Berger LPV, van Asperen CJ, Adank MA, Collée MJ, Stommel-Jenner DJ, Jager A, Schmidt MK, Hooning MJ.
PMID: 34929424
Breast. 2021 Dec 14;61:98-107. doi: 10.1016/j.breast.2021.12.007. Epub 2021 Dec 14.

AIM: BRCA1/2 mutation carriers with primary breast cancer (PBC) are at high risk of contralateral breast cancer (CBC). In a nationwide cohort, we investigated the effects of chemotherapeutic agents given for PBC on CBC risk separately in BRCA1 and...

Cite
Akdeniz D, van Barele M, Heemskerk-Gerritsen BAM, et al. Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study. Breast. 2021;61:98-107doi: 10.1016/j.breast.2021.12.007.
Akdeniz, D., van Barele, M., Heemskerk-Gerritsen, B. A. M., Steyerberg, E. W., Hauptmann, M., van de Beek, I., van Engelen, K., Wevers, M. R., Gómez García, E. B., Ausems, M. G. E. M., Berger, L. P. V., van Asperen, C. J., Adank, M. A., Collée, M. J., Stommel-Jenner, D. J., Jager, A., Schmidt, M. K., & Hooning, M. J. (2021). Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study. Breast (Edinburgh, Scotland), 6198-107. https://doi.org/10.1016/j.breast.2021.12.007
Akdeniz, Delal, et al. "Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study." Breast (Edinburgh, Scotland) vol. 61 (2021): 98-107. doi: https://doi.org/10.1016/j.breast.2021.12.007
Akdeniz D, van Barele M, Heemskerk-Gerritsen BAM, Steyerberg EW, Hauptmann M, van de Beek I, van Engelen K, Wevers MR, Gómez García EB, Ausems MGEM, Berger LPV, van Asperen CJ, Adank MA, Collée MJ, Stommel-Jenner DJ, Jager A, Schmidt MK, Hooning MJ. Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study. Breast. 2021 Dec 14;61:98-107. doi: 10.1016/j.breast.2021.12.007. Epub 2021 Dec 14. PMID: 34929424; PMCID: PMC8693290.
Copy Download .nbib Format: NLM
Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study.

Breast (Edinburgh, Scotland)

Akdeniz D, van Barele M, Heemskerk-Gerritsen BAM, Steyerberg EW, Hauptmann M, van de Beek I, van Engelen K, Wevers MR, Gómez García EB, Ausems MGEM, Berger LPV, van Asperen CJ, Adank MA, Collée MJ, Stommel-Jenner DJ, Jager A, Schmidt MK, Hooning MJ.
PMID: 34929424
Breast. 2021 Dec 14;61:98-107. doi: 10.1016/j.breast.2021.12.007. Epub 2021 Dec 14.

AIM: BRCA1/2 mutation carriers with primary breast cancer (PBC) are at high risk of contralateral breast cancer (CBC). In a nationwide cohort, we investigated the effects of chemotherapeutic agents given for PBC on CBC risk separately in BRCA1 and...

Cite
Akdeniz D, van Barele M, Heemskerk-Gerritsen BAM, et al. Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study. Breast. 2021;61:98-107doi: 10.1016/j.breast.2021.12.007.
Akdeniz, D., van Barele, M., Heemskerk-Gerritsen, B. A. M., Steyerberg, E. W., Hauptmann, M., van de Beek, I., van Engelen, K., Wevers, M. R., Gómez García, E. B., Ausems, M. G. E. M., Berger, L. P. V., van Asperen, C. J., Adank, M. A., Collée, M. J., Stommel-Jenner, D. J., Jager, A., Schmidt, M. K., & Hooning, M. J. (2021). Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study. Breast (Edinburgh, Scotland), 6198-107. https://doi.org/10.1016/j.breast.2021.12.007
Akdeniz, Delal, et al. "Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study." Breast (Edinburgh, Scotland) vol. 61 (2021): 98-107. doi: https://doi.org/10.1016/j.breast.2021.12.007
Akdeniz D, van Barele M, Heemskerk-Gerritsen BAM, Steyerberg EW, Hauptmann M, van de Beek I, van Engelen K, Wevers MR, Gómez García EB, Ausems MGEM, Berger LPV, van Asperen CJ, Adank MA, Collée MJ, Stommel-Jenner DJ, Jager A, Schmidt MK, Hooning MJ. Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study. Breast. 2021 Dec 14;61:98-107. doi: 10.1016/j.breast.2021.12.007. Epub 2021 Dec 14. PMID: 34929424; PMCID: PMC8693290.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 19 entries